Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer

Aim - to investigate the quantitative and functional status of peripheral blood lymphocytes in patients with non-small cell lung cancer during DC-vaccine therapy and identify the most informative immunological parameters which are associated with clinical outcome. The study was conducted within the...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2013
Автори: Skachkova, O.V., Khranovska, N.M., Gorbach, O.I., Svergun, N.M., Sydor, R.I., Nikulina, V.V.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/145215
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer / O.V. Skachkova, N.M. Khranovska, O.I. Gorbach, N.M. Svergun, R.I. Sydor, V.V. Nikulina // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 109-113. — Бібліогр.: 14 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
Опис
Резюме:Aim - to investigate the quantitative and functional status of peripheral blood lymphocytes in patients with non-small cell lung cancer during DC-vaccine therapy and identify the most informative immunological parameters which are associated with clinical outcome. The study was conducted within the framework of randomized phase III clinical trial of DC-vaccine efficacy in patients with non-small cell lung cancer. Quantitative composition of peripheral blood lymphocytes was determined by flow cytometry. Cytokines mRNA expression level was estimated using real-time RT-PCR. In our study the most pronounced changes in the immune system have been defined after fourth DC-vaccine injection. Immunologic features such as reduction the MIP-1 alpha mRNA expression level, increasing the RANTES mRNA expression level and NK-cells count, retention CD4/CD8 ratio at physiological level were associated with favorable clinical outcome after DC-immunotherapy. Conclusions: immunological markers established in our investigation can be used for estimation of DC-immunotherapy efficiency. The results of our research are very promising, but these data should be confirmed in further studies with a large cohort of patients. Key Words: lung cancer, DC-vaccine, immunological monitoring, effector cells, chemokines.